Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cell immunity
Jonas S. Heitmann, Tatjana Bilich, Claudia Tandler, et al.
Nature (2021) Vol. 601, Iss. 7894, pp. 617-622
Open Access | Times Cited: 211

Showing 1-25 of 211 citing articles:

The T cell immune response against SARS-CoV-2
Paul Moss
Nature Immunology (2022) Vol. 23, Iss. 2, pp. 186-193
Open Access | Times Cited: 1085
COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety
Annika Fendler, Elisabeth G.E. de Vries, Corine H. GeurtsvanKessel, et al.
Nature Reviews Clinical Oncology (2022) Vol. 19, Iss. 6, pp. 385-401
Open Access | Times Cited: 178
Disentangling the relative importance of T cell responses in COVID-19: leading actors or supporting cast?
Stephen J. Kent, David S. Khoury, Arnold Reynaldi, et al.
Nature reviews. Immunology (2022) Vol. 22, Iss. 6, pp. 387-397
Open Access | Times Cited: 119
T Cell Responses to SARS-CoV-2
Alessandro Sette, John Sidney, Shane Crotty
Annual Review of Immunology (2023) Vol. 41, Iss. 1, pp. 343-373
Closed Access | Times Cited: 114
Toll-like receptor (TLR) agonists as a driving force behind next-generation vaccine adjuvants and cancer therapeutics
Arshpreet Kaur, Jeremy Baldwin, Deshkanwar Brar, et al.
Current Opinion in Chemical Biology (2022) Vol. 70, pp. 102172-102172
Open Access | Times Cited: 96
Adaptive Immune Responses and Immunity to SARS-CoV-2
Dragan Primorac, Kristijan Vrdoljak, Petar Brlek, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 90
Recent Advances in the Development of Toll-like Receptor Agonist-Based Vaccine Adjuvants for Infectious Diseases
Jingxing Yang, Jen‐Chih Tseng, Guann‐Yi Yu, et al.
Pharmaceutics (2022) Vol. 14, Iss. 2, pp. 423-423
Open Access | Times Cited: 80
Decoding Toll-like receptors: Recent insights and perspectives in innate immunity
Taro Kawai, Moe Ikegawa, Daisuke Ori, et al.
Immunity (2024) Vol. 57, Iss. 4, pp. 649-673
Open Access | Times Cited: 69
Insights into vaccines for elderly individuals: from the impacts of immunosenescence to delivery strategies
Yingying Hou, Min Chen, Yuan Bian, et al.
npj Vaccines (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 20
Human coronavirus OC43-elicited CD4+ T cells protect against SARS-CoV-2 in HLA transgenic mice
Rúbens Prince dos Santos Alves, Julia Timis, Robyn Miller, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 13
A review on current status of antiviral peptides
Abid Qureshi
Discover Viruses. (2025) Vol. 2, Iss. 1
Open Access | Times Cited: 1
Developing T Cell Epitope-Based Vaccines Against Infection: Challenging but Worthwhile
Xian Tang, Wei Zhang, Zheng Zhang
Vaccines (2025) Vol. 13, Iss. 2, pp. 135-135
Open Access | Times Cited: 1
Immunogenicity and reactogenicity of SARS-CoV-2 vaccines BNT162b2 and CoronaVac in healthy adolescents
Jaime S. Rosa Duque, Xiwei Wang, Daniel Leung, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 56
Immunocompromised Patients with Protracted COVID-19: a Review of “Long Persisters”
M. Veronica Dioverti, Sonsoles Salto‐Alejandre, Ghady Haidar
Current Transplantation Reports (2022) Vol. 9, Iss. 4, pp. 209-218
Open Access | Times Cited: 56
The MHC Motif Atlas: a database of MHC binding specificities and ligands
Daniel M. Tadros, Simon Eggenschwiler, Julien Racle, et al.
Nucleic Acids Research (2022) Vol. 51, Iss. D1, pp. D428-D437
Open Access | Times Cited: 40
Adjuvant physiochemistry and advanced nanotechnology for vaccine development
Hongze Ren, Wencong Jia, Yujie Xie, et al.
Chemical Society Reviews (2023) Vol. 52, Iss. 15, pp. 5172-5254
Closed Access | Times Cited: 30
Trial watch: Toll-like receptor ligands in cancer therapy
Julie Le Naour, Guido Kroemer
OncoImmunology (2023) Vol. 12, Iss. 1
Open Access | Times Cited: 26
Toward a pan-SARS-CoV-2 vaccine targeting conserved epitopes on spike and non-spike proteins for potent, broad and durable immune responses
Chang Yi Wang, Wen‐Jiun Peng, Be-Sheng Kuo, et al.
PLoS Pathogens (2023) Vol. 19, Iss. 4, pp. e1010870-e1010870
Open Access | Times Cited: 24
SARS-CoV-2: Immunity, Challenges with Current Vaccines, and a Novel Perspective on Mucosal Vaccines
Raju Sunagar, Amit Kumar Singh, Sudeep Kumar
Vaccines (2023) Vol. 11, Iss. 4, pp. 849-849
Open Access | Times Cited: 23
TiO2-based photocatalysts for emerging gaseous pollutants removal: From photocatalysts to reactors design
Chinnadurai Ayappan, Ruimin Xing, Xintong Zhang, et al.
Coordination Chemistry Reviews (2024) Vol. 515, pp. 215960-215960
Closed Access | Times Cited: 13
A third vaccination with a single T cell epitope confers protection in a murine model of SARS-CoV-2 infection
Iris N. Pardieck, Tetje C. van der Sluis, Esmé T.I. van der Gracht, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 36
The oncogenic fusion protein DNAJB1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinoma
Jens Bauer, Natalie Köhler, Yacine Maringer, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 36
Cell-penetrating peptides enhance peptide vaccine accumulation and persistence in lymph nodes to drive immunogenicity
Coralie M. Backlund, Rebecca L. Holden, Kelly D. Moynihan, et al.
Proceedings of the National Academy of Sciences (2022) Vol. 119, Iss. 32
Open Access | Times Cited: 35
Mild SARS-CoV-2 infection in rhesus macaques is associated with viral control prior to antigen-specific T cell responses in tissues
Christine E Nelson, Sivaranjani Namasivayam, Taylor W. Foreman, et al.
Science Immunology (2022) Vol. 7, Iss. 70
Open Access | Times Cited: 30
Current progress in the development of prophylactic and therapeutic vaccines
Tingting Li, Ciying Qian, Ying Gu, et al.
Science China Life Sciences (2022) Vol. 66, Iss. 4, pp. 679-710
Open Access | Times Cited: 30
Page 1 - Next Page

Scroll to top